Viatris (VTRS) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with VTRS
Recent news

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
VTRS

Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
VTRS

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
VTRS

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
VTRS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.67
- MACD 12/26/9
- 0.16
- EMA 9 of MACD
- 0.21
- MACD histogram
- -0.05
- SMA 50
- $16.92
- Price above SMA 50
- EMA 50
- $17.08
- Price above EMA 50
- SMA 200
- $15.51
- Price above SMA 200
- EMA 200
- $15.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.63 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
VTRS

Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
VTRS

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
VTRS

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
VTRS

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS

HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
VTRS

Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
VTRS

Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion
Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion
VTRS

VTRS vs. AVTR: Which Stock Is the Better Value Option?
VTRS vs. AVTR: Which Stock Is the Better Value Option?
VTRS

Should Value Investors Buy Viatris (VTRS) Stock?
Should Value Investors Buy Viatris (VTRS) Stock?
VTRS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Viatris
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott Andrew Smith Ph.D. | CEO & Director | 1962 |
| Mr. Paul B. Campbell | Interim CFO, Chief Accounting Officer & Corporate Controller | 1967 |
| Mr. Andrew Enrietti | Chief Administrative & Transformation Officer | 1985 |
| Dr. Corinne M. Le Goff M.B.A., Pharm.D. | Chief Commercial Officer | 1965 |
| Mr. Ramkumar V. Rayapureddy | Chief Information Officer | — |
| Mr. William Szablewski C.F.A. | Head of Investor Relations & Capital Markets | — |
| Mr. Matthew Joseph Maletta | Chief Legal Officer | 1972 |
| Ms. Lara Ramsburg | Chief People & Corporate Affairs Officer | — |
| Mr. Philippe Martin | Chief R&D Officer | 1976 |
| Mr. Peter McCormick | Chief Supply Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 48.67
- MACD 12/26/9
- 0.16
- EMA 9 of MACD
- 0.21
- MACD histogram
- -0.05
- SMA 50
- $16.92
- Price above SMA 50
- EMA 50
- $17.08
- Price above EMA 50
- SMA 200
- $15.51
- Price above SMA 200
- EMA 200
- $15.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $13.00
- Average
- $20.80
- High
- $26.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.8 | -10.9 | +11.9 | |||||||||
| 2022 | +5.3 | -26.9 | +7.2 | -4.5 | +20.2 | -13.3 | -9.5 | -1.1 | -11.0 | +16.2 | +7.6 | -1.0 |
| 2023 | +6.9 | -7.0 | -14.9 | -2.9 | -2.2 | +8.7 | +6.5 | +5.2 | -8.6 | -11.4 | +2.9 | +15.6 |
| 2024 | +3.3 | +4.2 | -5.2 | -3.1 | -8.9 | +0.5 | +13.9 | +1.0 | -2.4 | +1.0 | +12.7 | -5.7 |
| 2025 | -9.2 | -16.4 | -6.6 | -2.1 | +3.8 | +2.8 | -4.8 | +19.8 | -6.3 | +2.7 | +1.5 | +16.4 |
| 2026 | +5.1 | +9.1 | -13.9 | +9.6 | +8.1 | +0.4 | +8.5 | -6.4 | +6.6 | +0.5 |
Corporate actions
Upcoming
No upcoming corporate actions for VTRS



